AbbVie to lead new research into adverse drug reactions

AbbVie has been appointed project leader of a new collaborative research initiative focusing on the prevention of adverse drug reactions.

The five-year project, called Translational Quantitative Systems Toxicology to Improve the Understanding of the Safety of Medicines, will create novel approaches to address the problems of drug safety, using the best available data from the public and private domains.

A total of ten academic institutions, three small and medium-sized enterprises and eight pharmaceutical companies will work together on the 14 million pound project, which will be coordinated by the University of Liverpool and led by AbbVie.

One key focus of the project will be off-target reactions that cannot be predicted from the known pharmacological properties of a given drug, and often affect organs such as the liver, the kidneys and the cardiovascular and gastrointestinal systems.

Project coordinator Professor Kevin Park, from the University of Liverpool's Institute of Translational Medicine, said: "This project will enable us to leverage the best available data and expertise from both public and private domains to generate and validate novel computational models that will help to address the problems of safe drug development."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.